Prevention of chronic kidney disease: The next step forward! (Review Article)
Open Access
- 1 June 2006
- journal article
- review article
- Published by Wiley in Nephrology
- Vol. 11 (3) , 240-244
- https://doi.org/10.1111/j.1440-1797.2006.00575.x
Abstract
The incidence of end stage renal disease in patients who have not experienced a classic primary renal disease is dramatically increasing. Chronic kidney disease (CKD) in these patients is due to diabetes, mostly type 2, hypertension and generalised atherosclerosis. As these patients are frequently diagnosed as having renal function impairment only in the late phase, more effort should be undertaken to diagnose them earlier, that is, at a time when renoprotective measures can still be undertaken. For that purpose, measurement of the estimated glomerular filtration rate (GFR) might be helpful. To properly interpret those measurements, however, we need to be aware of the pros and cons of the use of formulas to estimate the GFR. Most likely, a better way to detect subjects at risk of CKD in the early phase is screening by dipstick proteinuria or preferably by testing for (micro-) albuminuria. Because microalbuminuria not only indicates increased renal but also enhanced cardiovascular risk, the benefits of such screening programmes may have a much greater affect than only preventing renal disease.Keywords
This publication has 36 references indexed in Scilit:
- Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future?Kidney International, 2004
- Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal DiseaseDiabetes Care, 2004
- Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-AnalysisAnnals of Internal Medicine, 2003
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathyThe Lancet, 1997
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal InsufficiencyNew England Journal of Medicine, 1996
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993
- Prediction of Clinical Diabetic Nephropathy in IDDM Patients: Alternatives to Microalbuminuria?Diabetes, 1990
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976